Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Calcium+Company, a 2025 MM+M Agency 100 honoree, named Susan Goldstein as an EVP who has joined the Protein team. Bobby ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Shares of Nurix Therapeutics rose after the company said it will receive a $15 million license extension fee from Sanofi for its STAT6 program. The stock climbed 11% to $11.76 on Monday. Shares have ...